BioSpace News Archive

Certis provides high-precision translational drug discovery and development services to therapeutics innovators.

BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, announced the closing and funding of its previously announced best efforts underwritten public offering.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced the pricing of its underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $2.10 per share.

MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2022.

The global respiratory care devices market has been gaining traction in the last few years.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global gene therapy market advocates that the industry is poised to incline at an 18.5% value CAGR from 2022-2032, expected to close at a valuation of US$ 10.1 Billion.

Wilmington, Delaware, United States: The growth of the global market viral inactivation hinges on to advancements in the fields of drug development, microbiology, and medication.

International medical imaging IT and cybersecurity company Sectra has signed a contract with Niagara Health System in Canada.

Oculis S.A. announced that the first patient has been enrolled in its Phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01, a novel, high concentration, preservative-free, topical OPTIREACH formulation of dexamethasone for the treatment of inflammation and pain following cataract surgery.

Aesthetic Medical International Holdings Group Limited, a leading provider of aesthetic medical services in China, announced its unaudited financial results for the first quarter ended March 31, 2022.